3SBio of Shenyang acquired Zhejiang Wansheng Pharma, a small molecule drugmaker with a compatible portfolio of products, paying $85 million; Ally Bridge Group, a Hong Kong-US investment firm, opened a hedge fund that invests in listed China life science companies; Shenzhen Hepalink Pharma closed its $27 million acquisition of greater China rights to a cardiovascular drug from Canada's Resverlogix; Phagelux, a Shanghai company that is developing phage-based anti-bacterial products, acquired fellow phage company, Utah's OmniLytics; OrbusNeich, headquartered in Hong Kong, enrolled the first patient in a China clinical trial of its COMBO™ Dual Therapy Stent; Eddingpharm of Hong Kong plans to start a China Phase I trial of Brinavess, a drug developed by Cardiome Pharma of Canada to treat atrial fibrillation; Micell Technologies of North Carolina started enrolling patients in a China registrational trial of its drug eluting stent, the MiStent SES®; CASI Pharma, a US-China pharma, reported that Zevalin®, a treatment for non-Hodgkin's lymphoma, is now available in Hong Kong.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
